FarmaForum, the Slovenian innovative pharmaceutical industry association recognizes the need for comprehensive regulations and standards and welcomes the European Commission legislative initiative aimed at modernising the pharmaceutical legislation.
FIR
Forum of International Research and Development Pharmaceutical Companies, EIG
Industry association · Slovenia
6
positions filed
in the 583 files tracked
4
legislative files
of 583 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track Forum in PolicySpeak: request access →
Work at Forum of International Research and Development Pharmaceutical Companies, EIG? so we know who speaks for it.
Their record over time
Forum of International Research and Development Pharmaceutical Companies, EIG filed 6 positions between 6 Jan 2021 and 21 Oct 2023, across 4 of the 583 legislative files tracked here.
2021 · 3 filed2023 · 3 filed
What they argued
FarmaForum, the Slovenian innovative pharmaceutical industry association recognizes the need for comprehensive regulations and standards and welcomes the European Commission legislative initiative aimed at modernising the pharmaceutical legislation.
Forum, as a Slovenian R&D pharmaceutical industry association, hereby expresses its support of the European Commission's effort to build a regulatory framework which will ensure availability of innovative, effective and safe medicines throughout the whole European union and that all needs of European patients will be adequately addressed.
Forum’s views on the proposed European Health Data Space (EHDS) Forum, the Slovenian innovative pharmaceutical association, which represents 21 global research companies, supports the Commission's efforts to generate a legal environment providing for a wide-ranging use, re-use and exchange of health data, acknowledging the value of such data and promoting the harmonization of digital standards, both at the EU and at…
In Forum, the Slovenian innovative pharmaceutical association, which represents 22 global research companies, we are aware, that to date, the Paediatric and Orphan Regulations have provided immense benefits for children and patients with rare diseases (RD) in Slovenia. We would welcome Commission’s effort to maintain the legislative framework which would ensure possibilities to treat DS also in the future.
Forum of International Research and Development Pharmaceutical Companies, EIG (FarmaForum), as a Slovenian innovative pharma industry association, expresses its concern regarding the European Commission's (EC) proposal of the new compulsory licensing legislation. The EC's proposal introduces a new right to issue compulsory licenses throughout the EU, which the EC would activate in a "crisis" situation.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Forum of International Research and Development Pharmaceutical Companies, EIG next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 94.
Is this your organization?
Everything on this page comes from Forum of International Research and Development Pharmaceutical Companies, EIG’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.